Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

Affiliations

• ¹ Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
• ² Metrum Research Group LLC, Tariffville, CT, USA.
• ³ Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
• ⁴ Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
• ⁵ Takeda Development Centre Europe Ltd, London, UK.
• ⁶ Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
• ⁷ Robarts Research Institute, University of Western Ontario, London, ON, Canada.
• ⁸ Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
• ⁹ Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.